Status:
COMPLETED
AryoTrust® (Trastuzumab) Safety Study
Lead Sponsor:
AryoGen Pharmed Co.
Conditions:
Breast Cancer
Eligibility:
All Genders
Brief Summary
This study was a phase IV, observational, multicenter, single-arm, open-label, post-marketing surveillance study for the assessment of AryoTrust safety in Iranian HER2-positive breast cancer patients ...
Detailed Description
The present study is an observational, multicenter, non-interventional, single-arm, open-label PMS study conducted in Iran. No control groups are included in the study design. The objective of this P...
Eligibility Criteria
Inclusion
- Patients with HER2-positive breast cancer undergoing adjuvant chemotherapy regimens
Exclusion
- Patients who had received Trastuzumab as part of their therapy or were not candidates for treatment continuation after adjuvant chemotherapy
Key Trial Info
Start Date :
February 22 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 28 2022
Estimated Enrollment :
597 Patients enrolled
Trial Details
Trial ID
NCT06021379
Start Date
February 22 2017
End Date
August 28 2022
Last Update
October 31 2023
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
5th Azar Hospital
Gorgan, Iran
2
Milad Hospital
Isfahan, Iran
3
Mahdieh Clinic
Kermanshah, Iran
4
Hashemi Nezhad Hospital
Mashhad, Iran